Cardiac Transplantation Clinical Trial
Official title:
Absolute Myocardial Perfusion Measurement in the Transplanted Heart: a New Method for Accurate Detection of Allograft Rejection. A Pilot Study
The goal of this study is to detect AR and CR in the transplanted heart by quantitative assessment of myocardial blood flow and its constituents by myocardial contrast echocardiography (MCE). Further we investigate the collateral circulation in these patients.
Heart transplantation has become an accepted therapy for end-stage heart failure. Acute
allograft rejection (AR) remains a major cause of mortality in heart transplant recipients.
Chronic rejection (CR) determines the long-term prognosis after cardiac transplantation and
is responsible for more than one third of late deaths. Different non-invasive methods have
been evaluated for the detection of AR, but the gold standard remains endomyocardial biopsy
(EMB).
Very little is known about the impact of CR on the collateral circulation in transplant
patients. Since the collateral circulation of the heart is mainly part of the
microcirculation, it can be hypothesized that it is less developed than in "normal" coronary
atherosclerosis without microvascular lesions.
The quantification of CR with non-invasive techniques has remained difficult. In this
context, there is a need for a reliable non-invasive test to avoid regularly invasive
evaluation.
Based on the above considerations we propose that both AR and CR can be accurately detected
and differentiated using non-invasive quantitative myocardial contrast echocardiography
(MCE).
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02672683 -
Non Invasive Detection of Cardiac Allograft Rejection by Circulating microRNAs
|
||
Completed |
NCT01017029 -
Everolimus in de Novo Heart Transplant Recipients
|
Phase 4 | |
Terminated |
NCT00338455 -
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
|
Phase 2 | |
Completed |
NCT00170794 -
Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
|
Phase 3 | |
Completed |
NCT00000412 -
Osteoporosis Prevention After Heart Transplant
|
Phase 3 | |
Completed |
NCT00716573 -
Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
|
Phase 4 | |
Completed |
NCT02255123 -
Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study
|
N/A | |
Active, not recruiting |
NCT00799188 -
CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial
|
Phase 3 | |
Terminated |
NCT00284531 -
Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05904678 -
Anatomical and Functional Assessment of Ex-vivo Coronary Perfusion
|
||
Terminated |
NCT01235910 -
Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation
|
Phase 4 | |
Active, not recruiting |
NCT00581321 -
Oral Water Ingestion in Heart Transplant Patients
|
N/A | |
Terminated |
NCT00166153 -
Outcomes in Pediatric Heart Transplant Recipients Receiving Cellcept
|
N/A | |
Completed |
NCT03145441 -
Intraoperative Use of Extracorporeal Cytokine Adsorption During Orthotopic Heart Transplantation
|
N/A |